<DOC>
	<DOC>NCT00593255</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.</brief_summary>
	<brief_title>Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 or 2 diabetes for at least 4 weeks Treatment with oral antidiabetic drugs (OADs) and/or insulin for at least 4 weeks HbA1c: 7.513.5% Body Mass Index (BMI): 1835 kg/m2 Treatment with either soluble human insulin or insulin NPH three times daily within 3 months before trial participation History of drug abuse or alcohol dependence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>